Codexis Announces CEO Transition Effective August 9, 2022
July 18 2022 - 4:05PM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company
enabling the promise of synthetic biology, today announced that its
Board of Directors appointed Dr. Stephen Dilly, former CEO of
Sierra Oncology, Inc. and current Codexis Board member, as the
company’s President and CEO, effective August 9, 2022. John
Nicols will retire as President and CEO for family reasons after
leading the company’s transformation and subsequent growth for the
last decade. Mr. Nicols will remain on Codexis’ Board through the
annual meeting in June 2023 and will assume a new multi-year role
as Strategic Advisor to provide ongoing support to the company.
“We are delighted that Stephen will serve as
Codexis’ next CEO. He is a proven leader with a long track record
of success building innovative companies. With Stephen taking over
the helm, I can step back and provide the needed focus and support
to my wife who has suffered for years from a debilitating
post-viral infection disorder, and dedicate more time to make a
difference for her and the many others who face similar challenges
through the non-profit that I chair,” said John Nicols, President
and CEO of Codexis.
“The company is well-positioned to continue its
significant growth, and we have tremendous confidence that
Stephen’s extensive and relevant experience will serve to amplify
our existing success,” said Byron Dorgan, Chair of the Board
of Codexis. “With his years of leadership serving on Codexis’
Board, and coupled with John’s ongoing support and involvement,
Stephen is uniquely positioned to lead Codexis into its next
exciting chapter of growth.”
“I am energized by the opportunity to lead
Codexis in sustainable manufacturing, life science tools and
biotherapeutic discovery. Our world-leading CodeEvolver® enzyme
engineering platform technology has unmatched potential to deliver
important real world commercial benefits and impact,” said Dr.
Dilly. “I have been deeply impressed by the strength and passion of
the team that John has built, and I am honored to succeed him and
lead Codexis on the next phase of our important journey to improve
the health of people and the planet. I look forward to further
accelerating the value we bring to all our stakeholders.”
“On behalf of Codexis and the Board, I would
like to thank John for his outstanding leadership and deep
commitment to the company. During his tenure, Codexis has
transformed itself into a high growth, recapitalized enterprise
bringing increasing value and innovation to some of the world’s
most important partners and markets,” said Mr. Dorgan. “Under
John’s leadership, the company has consistently built and grown our
product revenues, boldly and successfully entered the highly
dynamic life sciences sector and proven the CodeEvolver® platform
as a differentiated drug discovery engine.”
“I am incredibly proud to have had the
opportunity to lead Codexis over the past decade,” said Mr.
Nicols. “Codexis is stronger and better positioned than ever, with
an incredibly talented team in place. I am grateful to the entire
Codexis team for their dedication, hard work and collaborative
spirit, and for helping us become such an exciting company to work
for and with. We are only seeing the beginning of the long-term
benefits that Codexis, its team and technology can bring to our
world. It will be my pleasure to continue to be involved in
supporting Stephen and the Board to help take Codexis to even
greater success and impact in its next chapter of growth.”
Stephen G. Dilly, MBBS, Ph.D., brings more than
three decades of executive management experience in the
biopharmaceutical industry. Most recently, he served as President
and CEO of Sierra Oncology (NASDAQ: SRRA) through its recent sale
to GlaxoSmithKline for $1.9 billion. Previously, Dr. Dilly served
as CEO of Aimmune Therapeutics, acquired by Nestle Health Science
for $2.6 billion. Dr. Dilly has served in executive roles at
Genentech, Chiron and SmithKline Beecham and has been associated
with the development, approval and launch of more than twenty
marketed drugs across multiple therapeutic areas. He holds both an
MBBS and a Ph.D. in Cardiac Physiology from the University of
London.
About Codexis
Codexis is a leading enzyme engineering company
leveraging its proprietary CodeEvolver® platform to discover and
develop novel, high performance enzymes and novel biotherapeutics.
Codexis enzymes have applications in the sustainable manufacturing
of pharmaceuticals, food, and industrial products; in the creation
of the next generation of life science tools; and as gene therapy
and oral enzyme therapies. The company’s unique performance enzymes
drive improvements such as: reduced energy usage, waste generation
and capital requirements; higher yields; higher fidelity
diagnostics; and more efficacious therapeutics. Codexis enzymes
enable the promise of synthetic biology to improve the health of
people and the planet. For more information, visit
www.codexis.com.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Codexis, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. You should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties and other factors that are, in some cases,
beyond Codexis’ control and that could materially affect actual
results. Additional information about factors that could materially
affect actual results can be found in Codexis’ Annual Report on
Form 10-K filed with the Securities and Exchange Commission (“SEC”)
on February 28, 2022, and in Codexis’ Quarterly Report on Form 10-Q
filed with the SEC on May 9, 2022, including under the caption
“Risk Factors,” and in Codexis’ other periodic reports filed with
the SEC. Codexis expressly disclaims any intent or obligation to
update these forward-looking statements, except as required by
law.
Investor Relations Contact:Argot
PartnersBrendan Strong/Carrie McKim(212)
600-1902Codexis@argotpartners.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Aug 2023 to Aug 2024